DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas2. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma 3. Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes4. Redefining the standard of care for low-grade serous ovarian cancer5. The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers6. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific
